Joma K. Joy

10 Biopolis Road, Chromos #05-01
Singapore, 138670, Singapore

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Correction to "Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity".

Correction to "Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity".

Journal: Journal of medicinal chemistry

Published: December 23, 2025

In Silico-Enabled Discovery and Development of Potent and Selective CDK11 Inhibitors.

In Silico-Enabled Discovery and Development of Potent and Selective CDK11 Inhibitors.

Journal: ChemMedChem

Published: October 08, 2025

Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity.

Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity.

Journal: Journal of medicinal chemistry

Published: August 07, 2025

A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir.

A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir.

Journal: ACS medicinal chemistry letters

Published: May 31, 2022

Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphatase.

Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphatase.

Journal: Protein science : a publication of the Protein Society

Published: August 23, 2021

Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.

Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.

Journal: Bioorganic & medicinal chemistry

Published: July 16, 2021

A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.

A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: May 29, 2021

Strategic Design of Catalytic Lysine-Targeting Reversible Covalent BCR-ABL Inhibitors*.

Strategic Design of Catalytic Lysine-Targeting Reversible Covalent BCR-ABL Inhibitors*.

Journal: Angewandte Chemie (International ed. in English)

Published: April 20, 2021

Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2.

Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2.

Journal: Journal of medicinal chemistry

Published: January 08, 2020

Correction to "Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3".

Correction to "Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3".

Journal: ACS medicinal chemistry letters

Published: August 16, 2019

Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3.

Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3.

Journal: ACS medicinal chemistry letters

Published: April 15, 2019

Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells.

Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells.

Journal: Molecular cancer therapeutics

Published: November 01, 2018

Showing 1-12 of 28

Last Updated: 09/26/2026